News

At the 2025 ASCRS meeting, Dr Ang said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery

At ARVO 2025, in Salt Lake City, Utah, Patipol Tiyajamorn, talked about his poster on using graph neural networks to identify fast glaucoma progressors solely using optic nerve head morphology at a single time point

Prof Alió was commended for his work in microincisional cataract surgery and accommodative IOLs for presbyopia

Retina specialist Priya Vakharia, MD, reveals promising ANX007 trial results, showing potential to prevent vision loss in geographic atrophy.

At ARVO 2025, in Salt Lake City, Utah, Anisha Kasi talked about her presentation on how her team used the TriNetX database, a large database of over 150 million patients worldwide, to validate the connection between hidradenitis suppurativa and inflammatory eye conditions.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

At ARVO 2025, in Salt Lake City, Utah, Xiaolin Wang, MS, talked about her presentation on in vivo imaging of retinal pigment epithelium metabolic function in AMD.

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

At ARVO 2025, in Salt Lake City, Utah, Noemi Guemes-Villahoz, MD, PhD, talked about 12-month results of vision-related quality of life in myopic children using combination treatment with atropine and DIMS (Defocus Incorporated Multiple Segments) spectacle lenses.

The recent study details the diagnostic value of a multimodal model utilizing both types of biomarkers when compared to unimodal models.

New research links diffuse-trickling patterns in fundus autofluorescence to increased ellipsoidal zone loss, highlighting potential biomarkers for rapid geographic atrophy progression.

Matthew Starr, MD, highlights the RHONE-X trial's findings on faricimab, showcasing improved vision and reduced treatment burden for diabetic macular edema patients.

The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities

At ARVO 2025, in Salt Lake City, Utah, Peng Shang, PhD, talked about her presentation on how the Y402H polymorphism of Complement Factor H (CFH), a major genetic risk factor for AMD, and chronic oxidative stress affect the lipid profile of retinal pigment epithelial (RPE) cells.

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

LUMIFY eye drops were initially introduced by Bausch + Lomb in 2018 and remain the only OTC redness relievers that selectively target eye redness with a lower risk of rebound redness and loss of efficacy when used as directed.

At ARVO 2025, in Salt Lake City, Utah, David Almeida, MD, MBA, PhD, talked about 12-month results from the PAVIA phase 2 trial of EYP-1901 in nonproliferative diabetic retinopathy.

DREAM is an acronym for deep imaging depth, rapid sweeping speed, extensive scan range, accurate results, and multimodal imaging capabilities.

Kapil Mishra, MD, discusses his presentation title "Radiation Retinopathy: Future Strategies" given at the 2025 Retina World Congress meeting.

Detecting mitochondrial dysfunction may give clinicians a chance to reduce the rate of cognitive decline in patients with dementia

At ARVO 2025, in Salt Lake City, Utah, Danielle Gauthier talked about her poster on autosomal dominant Alzheimer disease in relation to optic nerve head drusen.

In total, 613,690 images used for screening were included in the study.

At ARVO 2025, in Salt Lake City, Utah, Roger Goldberg, MD, MBA, talked about his presentation on the effect of AREDS vitamins in geographic atrophy.

Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its potential as a leading therapy.